Two stocks are standing out in premarket trading this Wednesday morning. Moderna (Nasdaq: MRNA) is up 8.9% and Ross Stores (Nasdaq: ROSS) is up 6.6% as of 8:00 AM ET, each moving on a distinct ...

Merck MRK-1.27%decrease; red down pointing triangle is shaking up the leadership of its main pharmaceutical unit as the U.S. drugmaker braces for sales pressure later this decade. The Rahway, ...

Merck & Co., Inc. (NYSE: MRK) has had a fantastic six months, seeing its share price go up nearly 50%. The company has a valuable portfolio of assets that will enable strong shareholder returns, ...

Shares of Merck & Co. Inc. MRK rose 1.82% to $121.93 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.97% to 6,932.30 and the ...

Merck forecasts 2026 sales below Wall Street estimates Co plans to offer clarity on $70 billion growth opportunities by 2027 Merck anticipates $2.5 billion impact from generic competition, Medicare ...

Merck earns a cautious "Buy" rating due to an intriguing valuation and clear, somewhat manageable uncertainties, especially post-Keytruda expiry in 2028. MRK's heavy reliance on Keytruda poses risk, ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

German tech giant Merck has inaugurated a new US$580 million semiconductor facility in Kaohsiung. The "Mega Site" will produce critical materials for AI and memory chips, specifically focusing on thin ...

That term has become the industry shorthand for assuring people nervous about AI’s increasing foothold in healthcare. There’s always someone watching over what AI does. We are there to make sure ...

FRANKFURT, Nov 13 (Reuters) - Merck KGaA (MRCG.DE), opens new tab on Thursday reported a slight gain in third-quarter operating earnings that beat market expectations, benefiting from legislative ...

Merck reported third-quarter earnings and revenue that topped estimates in part due to strong demand for its cancer immunotherapy Keytruda, and narrowed its full-year profit outlook to reflect lower ...